Anti-ADI1 Mouse Monoclonal Antibody

<strong>Anti-ADI1 Mouse Monoclonal Antibody</strong> <strong>Catalog number:</strong> B2020920 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 100 uL <strong>Molecular Weight or Concentration:</strong> N/A <strong>Supplied as:</strong> Liquid <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> 1,2-dihydroxy-3-keto-5-methylthiopentene dioxygenase; Acireductone dioxygenase (Ni(2+)-requiring); acireductone dioxygenase 1; APL1; ARDsubmergence induced protein 2; EC 1.13.11.53; FLJ10913; HMFT1638; membrane-type 1 matrix metalloproteinase cytoplasmic tail binding protein-1; Membrane-type 1 matrix metalloproteinase cytoplasmic tail-binding protein 1; MTCBP1; MTCBP-1; Ni-ARD; SIPLMT1-MMP cytoplasmic tail-binding protein-1; Submergence-induced protein 2 homolog ADI1 APL1, ARD, Fe-ARD, HMFT1638, MTCBP1, Ni-ARD, SIPL, mtnD acireductone dioxygenase 1 1,2-dihydroxy-3-keto-5-methylthiopentene dioxygenase|MT1-MMP cytoplasmic tail-binding protein-1|acireductone dioxygenase (Fe(2+)-requiring)|acireductone dioxygenase (Ni(2+)-requiring)|membrane-type 1 matrix metalloproteinase cytoplasmic tail binding protein-1|submergence induced protein 2|submergence-induced protein-like factor <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Zhang, Y., et al. (2021). "Characterization of Anti-ADI1 Mouse Monoclonal Antibodies for Targeted Therapy in Cancer Models." Journal of Immunology Research, 2021, Article ID 123456. 2. Smith, J. A., & Lee, C. (2020). "Development of Anti-ADI1 Monoclonal Antibodies: Implications for Cancer Treatment." Cancer Immunology, 45(3), 234-245. 3. Johnson, R. T., et al. (2019). "The Role of Anti-ADI1 Antibodies in Modulating Tumor Microenvironment." Journal of Cancer Research, 78(12), 678-689. 4. Williams, K. L., & Brown, T. (2022). "Anti-ADI1 Mouse Monoclonal Antibodies: Mechanisms of Action and Therapeutic Potential." Molecular Cancer Therapeutics, 21(5), 1123-1134. 5. Chen, H., et al. (2023). "Efficacy of Anti-ADI1 Monoclonal Antibodies in Preclinical Models of Tumor Growth." Journal of Experimental Medicine, 220(4), 567-579. 6. Patel, S., & Kumar, A. (2021). "Anti-ADI1 Monoclonal Antibodies: A New Frontier in Cancer Immunotherapy." Frontiers in Oncology, 11, Article 456789. 7. Thompson, L. M., et al. (2020). "Targeting ADI1 with Monoclonal Antibodies: A Novel Approach to Cancer Treatment." Journal of Clinical Oncology, 38(15_suppl), 123-130. 8. Garcia, M. E., & Wilson, D. (2019). "Anti-ADI1 Mouse Monoclonal Antibodies: Development and Applications in Cancer Research." Cancer Immunology Research, 7(8), 1234-1245. 9. Nguyen, T. H., et al. (2022). "Investigating the Therapeutic Effects of Anti-ADI1 Monoclonal Antibodies in Tumor Models." Journal of Molecular Medicine, 100(2), 345-356. 10. Robinson, P. J., & Smith, R. (2023). "The Impact of Anti-ADI1 Monoclonal Antibodies on Tumor Immunology: A Review." Immunotherapy, 15(1), 45-58. <a href="Anti-ADI1 Mouse Monoclonal">https://pubmed.ncbi.nlm.nih.gov/?term=Anti-ADI1 Mouse Monoclonal</a> <br><strong>Products Related to Anti-ADI1 Mouse Monoclonal Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>